CXCL12- CXCR4在乳腺浸润性导管癌中的表达及临床意义

摘要

Objective:To discuss the expression of chemokine CXCL12 and its receptor CXCR4 in breast invasive ductal cancer,further to illustrate the role of CXCL12 and its receptor CXCR4 expression in breast cancer clinicohisto-logical characteristics. Methods:The expression of CXCL12 and its receptor CXCR4 was investigated in 200 invasive ductal breast cancer by immunohistochemistry. The relation of CXCL12 and its receptor CXCR4 expression or co -ex-pression and clinicohistological characteristics was analyzed. Results:CXCL12 positive expression in80 / 200(40. 0 % )breast cancer cases and CXCR4 positive expression in 96 / 200(48. 0% )cases of breast cancer. CXCL12 expression correlated with TNM stage(P < 0. 05). CXCR4 expression was significantly associated with lymph node metastasis and TNM stage(P < 0. 05). The results of immunohistochemistry demonstrated CXCL12 and CXCR4 co - expression in 29. 0%(58 / 200)breast cancer samples and the co - expression of CXCL12 and CXCR4 correlated with lymph node metastasis and TNM stage(P < 0. 01). Conclusion:The chemokine CXCL12 and its sole ligand CXCR4 played important role in the malignant of breast cancer. Co - expression of CXCL12 and CXCR4 act as one of significant clin-icohistological characteristics affecting the metastasis of breast ductal cancer.%目的：研究乳腺浸润性导管癌中趋化因子 CXCL12及其对应的特异趋化因子受体 CXCR4的表达，分析其与浸润性导管癌临床病理学特征的关系。方法：用免疫组化法研究200例乳腺浸润性导管癌中 CX-CL12、CXCR4的表达情况，并探讨二者单一表达或共表达与临床病理因素的相关性。结果：CXCL12在40%（80/200）浸润性乳腺癌中阳性表达，其与 TNM 分期和肿瘤大小相关（P <0.05）；CXCR4在48%（96/200）浸润性乳腺癌中阳性表达，其表达与浸润性乳腺癌的 TNM 分期相关（P <0.05）。CXCL12与 CXCR4共表达于29%（58/200）的浸润性乳腺癌，二者的共表达与 TNM 分期和淋巴结转移情况相关（ P <0.01）。结论：CX-CL12与 CXCR4共表达很可能是协同乳腺浸润性导管癌进展及淋巴结转移的重要因素，检测 CXCL12与 CX-CR4共表达比检测 CXCL12或 CXCR4单一分子标记更有意义。